Efficacy and Safety of Ensifentrine in Chinese Patients with Chronic Obstructive Pulmonary Disease: The ENHANCE-CHINA Randomized Clinical Trial
Ensifentrine significantly improved lung function and showed efficacy benefits in symptoms, quality of life improvement, and exacerbation reduction in Chinese individuals with COPD.
Authors
- Zhu Xiao (ORCID: https://orcid.org/0000-0001-7042-8860)
- Charlie Degui Chen
- Dongbo Tian
- Guoru Yang
- Junzhen Gao
- Zonghui Wei
- Tiebo Yang
- Ting Yang
- Limin Wang
- Fan Wu
- Chuntao Liu
- Juan Chen
- Wei Gu
- Xiao Liu
- Pixin Ran
- Yi Hu
- Yuanrong Dai
- Nanshan Zhong
- Limin Dong
- Liping Peng
- Jie Cao
- Yumin Zhou
- Zihui Wang
- Feng Xu
- Dan Zhu
Institutions
- Nuance Communications (Austria) (AT)
- Jilin University (CN)
- Sichuan University (CN)
- Wenzhou Medical University (CN)
- China-Japan Friendship Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- West China Hospital of Sichuan University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Qingzhou City People's Hospital (CN)
- Jiangxi Provincial People's Hospital (CN)
- Wuhan Pulmonary Hospital (CN)
- Weifang People's Hospital (CN)
- People's Hospital of Cangzhou (CN)
- Jiangxi Pingxiang People's Hospital (CN)
- First Hospital of Jilin University (CN)
- Ningxia Medical University (CN)
- Chengdu Fifth People's Hospital (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- First People's Hospital of Chongqing (CN)
- Jinhua Central Hospital (CN)
- Inner Mongolia Medical University (CN)
- Huazhong University of Science and Technology (CN)
- Nanjing Medical University (CN)
- Qiqihar Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- CHEST Journal
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.chest.2026.02.035
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00